Literature DB >> 15781882

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.

Adam C Berger1, Jeffrey Farma, Walter J Scott, Gary Freedman, Louis Weiner, Jonathan D Cheng, Hao Wang, Melvyn Goldberg.   

Abstract

PURPOSE: Attempts to improve survival of patients with esophageal cancer have been made using induction chemoradiotherapy (CRT) followed by surgery. A large single-center experience was reviewed to determine which treatment-related variables could predict survival and recurrence. PATIENTS AND METHODS: All patients undergoing esophagectomy between January 1994 and December 2002 were reviewed. Univariate and multivariate analyses were performed using log-rank and Cox proportional hazards models, and survival curves were estimated using the Kaplan-Meier method.
RESULTS: Of 171 patients with invasive cancer, 131 (77%) underwent preoperative CRT. The average age was 60 years, and most patients were male (85%). Operations performed included Ivor-Lewis (60%), transhiatal (8%), three-hole (23%), or left thoracoabdominal (8%) esophagectomy. Perioperative mortality rate was 5%. Median overall survival (OS) of the entire group was 33 months, and the 5-year OS rate was 26%. Induction CRT was associated with a 33% 5-year survival rate compared with 11% for surgery alone (P = .43). Patients downstaged to pathologic stage 0 or I had an improved OS and disease-free survival (DFS) compared with those patients who were not downstaged (P = .022). Additionally, the ability to perform an R0 resection was a significant factor for OS and DFS (n = 130; P < .0001 and P <.0002, respectively).
CONCLUSION: Response to CRT and the ability to perform an R0 resection are associated with significantly improved survival in patients with esophageal carcinoma.

Entities:  

Mesh:

Year:  2005        PMID: 15781882     DOI: 10.1200/JCO.2005.05.017

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  148 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer.

Authors:  Patrick J McLaren; Nathan W Bronson; Kyle D Hart; Gina M Vaccaro; Ken M Gatter; Charles R Thomas; John G Hunter; James P Dolan
Journal:  J Gastrointest Surg       Date:  2017-01-12       Impact factor: 3.452

Review 3.  Multi-modality therapy for cancer of the esophagus and GE junction.

Authors:  Mohamedtaki A Tejani; Barbara A Burtness
Journal:  Curr Treat Options Oncol       Date:  2012-09

4.  Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer.

Authors:  Arianna Barbetta; Tamar B Nobel; Smita Sihag; Meier Hsu; Kay See Tan; Manjit S Bains; James M Isbell; Yelena Y Janjigian; Abraham J Wu; Matthew J Bott; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2018-05-05       Impact factor: 4.330

5.  Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis.

Authors:  Zengyun Li; Peiliang Zhang; Qingtong Ma; Dongqing Wang; Tao Zhou
Journal:  Mol Clin Oncol       Date:  2017-04-10

6.  The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

7.  Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer.

Authors:  Faisal A Siddiqui; Katelyn M Atkins; Brian S Diggs; Charles R Thomas; John G Hunter; James P Dolan
Journal:  J Gastrointest Oncol       Date:  2014-04

8.  Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.

Authors:  Nastaran Neishaboori; Roopma Wadhwa; Graciela M Nogueras-González; Elena Elimova; Hironori Shiozaki; Kazuki Sudo; Nikolaos Charalampakis; Adarsh Hiremath; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Mariela A Blum; Jane E Rogers; Jeana L Garris; David C Rice; Ritsuko Komaki; Stephen G Swisher; Heath D Skinner; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Oncology       Date:  2015-03-05       Impact factor: 2.935

9.  Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Peter G Rose; James J Java; Mark A Morgan; Angeles Alvarez-Secord; Joshua P Kesterson; Frederick B Stehman; David P Warshal; William T Creasman; Parviz Hanjani; Robert T Morris; Larry J Copeland
Journal:  Gynecol Oncol       Date:  2016-09-28       Impact factor: 5.482

10.  Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma.

Authors:  Zheng Chen; Rama Saad; Peilin Jia; DunFa Peng; Shoumin Zhu; M Kay Washington; Zhongming Zhao; Zekuan Xu; Wael El-Rifai
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.